Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,854 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Non-coding recurrent mutations in chronic lymphocytic leukaemia.
Puente XS, Beà S, Valdés-Mas R, Villamor N, Gutiérrez-Abril J, Martín-Subero JI, Munar M, Rubio-Pérez C, Jares P, Aymerich M, Baumann T, Beekman R, Belver L, Carrio A, Castellano G, Clot G, Colado E, Colomer D, Costa D, Delgado J, Enjuanes A, Estivill X, Ferrando AA, Gelpí JL, González B, González S, González M, Gut M, Hernández-Rivas JM, López-Guerra M, Martín-García D, Navarro A, Nicolás P, Orozco M, Payer ÁR, Pinyol M, Pisano DG, Puente DA, Queirós AC, Quesada V, Romeo-Casabona CM, Royo C, Royo R, Rozman M, Russiñol N, Salaverría I, Stamatopoulos K, Stunnenberg HG, Tamborero D, Terol MJ, Valencia A, López-Bigas N, Torrents D, Gut I, López-Guillermo A, López-Otín C, Campo E. Puente XS, et al. Among authors: gonzalez m, gonzalez s, gonzalez b. Nature. 2015 Oct 22;526(7574):519-24. doi: 10.1038/nature14666. Epub 2015 Jul 22. Nature. 2015. PMID: 26200345
Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
Bosch F, Ferrer A, Villamor N, González M, Briones J, González-Barca E, Abella E, Gardella S, Escoda L, Pérez-Ceballos E, Asensi A, Sayas MJ, Font L, Altés A, Muntañola A, Bertazzoni P, Rozman M, Aymerich M, Giné E, Montserrat E. Bosch F, et al. Among authors: gonzalez m, gonzalez barca e. Clin Cancer Res. 2008 Jan 1;14(1):155-61. doi: 10.1158/1078-0432.CCR-07-1371. Clin Cancer Res. 2008. PMID: 18172266 Clinical Trial.
[Chronic lymphocytic leukemia].
Hernández JA, González M, Hernández JM. Hernández JA, et al. Among authors: gonzalez m. Med Clin (Barc). 2010 Jul 3;135(4):172-8. doi: 10.1016/j.medcli.2009.10.016. Epub 2009 Dec 31. Med Clin (Barc). 2010. PMID: 20045138 Spanish. No abstract available.
Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results.
Delgado J, Espinet B, Oliveira AC, Abrisqueta P, de la Serna J, Collado R, Loscertales J, Lopez M, Hernandez-Rivas JA, Ferra C, Ramirez A, Roncero JM, Lopez C, Aventin A, Puiggros A, Abella E, Carbonell F, Costa D, Carrio A, Gonzalez M; Grupo Español de Leucemia Linfatica Cronica; Grupo Español de Citogenetica Hematologica. Delgado J, et al. Among authors: gonzalez m. Br J Haematol. 2012 Apr;157(1):67-74. doi: 10.1111/j.1365-2141.2011.09000.x. Epub 2012 Jan 9. Br J Haematol. 2012. PMID: 22224845 Free article. Clinical Trial.
Molecular characterization of chronic lymphocytic leukemia patients with a high number of losses in 13q14.
Rodríguez AE, Hernández JÁ, Benito R, Gutiérrez NC, García JL, Hernández-Sánchez M, Risueño A, Sarasquete ME, Fermiñán E, Fisac R, de Coca AG, Martín-Núñez G, de Las Heras N, Recio I, Gutiérrez O, De Las Rivas J, González M, Hernández-Rivas JM. Rodríguez AE, et al. Among authors: gonzalez m. PLoS One. 2012;7(11):e48485. doi: 10.1371/journal.pone.0048485. Epub 2012 Nov 13. PLoS One. 2012. PMID: 23152777 Free PMC article.
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.
Abrisqueta P, Villamor N, Terol MJ, González-Barca E, González M, Ferrà C, Abella E, Delgado J, García-Marco JA, González Y, Carbonell F, Ferrer S, Monzó E, Jarque I, Muntañola A, Constants M, Escoda L, Calvo X, Bobillo S, Montoro JB, Montserrat E, Bosch F. Abrisqueta P, et al. Among authors: gonzalez y, gonzalez m, gonzalez barca e. Blood. 2013 Dec 5;122(24):3951-9. doi: 10.1182/blood-2013-05-502773. Epub 2013 Oct 11. Blood. 2013. PMID: 24124086 Free article. Clinical Trial.
Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption.
Delgado J, Salaverria I, Baumann T, Martínez-Trillos A, Lee E, Jiménez L, Navarro A, Royo C, Santacruz R, López C, Payer AR, Colado E, González M, Armengol L, Colomer D, Pinyol M, Villamor N, Aymerich M, Carrió A, Costa D, Clot G, Giné E, López-Guillermo A, Campo E, Beà S. Delgado J, et al. Among authors: gonzalez m. Haematologica. 2014 Nov;99(11):e231-4. doi: 10.3324/haematol.2014.108365. Epub 2014 Jul 4. Haematologica. 2014. PMID: 24997154 Free PMC article. No abstract available.
A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia.
González-Gascón Y Marín I, Hernández-Sánchez M, Rodríguez-Vicente AE, Sanzo C, Aventín A, Puiggros A, Collado R, Heras C, Muñoz C, Delgado J, Ortega M, González MT, Marugán I, de la Fuente I, Recio I, Bosch F, Espinet B, González M, Hernández-Rivas JM, Hernández JÁ; Grupo Español de Leucemia Linfática Crónica (GELLC); Grupo Cooperativo Español de Citogenética Hematológica (GCECGH). González-Gascón Y Marín I, et al. Among authors: gonzalez mt, gonzalez m. Hematol Oncol. 2016 Jun;34(2):84-92. doi: 10.1002/hon.2196. Epub 2015 Feb 17. Hematol Oncol. 2016. PMID: 25689772
7,854 results